argenx to Present at Upcoming Investor Conferences
ARGX 11.26.2024
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:Citi’s 2024 Global Healthcare Conference
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:7th Annual Evercore I&I HealthCONx Conference
Date of Upcoming Event:2024-12-05
Name of Upcoming Event:Piper Sandler’s 35th Annual Healthcare Conference

About Gravity Analytica
Recent News
- 01.13.2025 - argenx Highlights 2025 Strategic Priorities
- 01.06.2025 - argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
- 12.27.2024 - argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
Recent Filings
- Citi’s 2024 Global Healthcare Conference.Fireside chat on
Tuesday, December 3 at1:45 p.m. ET inMiami, FL. - 7thAnnual
Evercore I&I HealthCONx Conference .Fireside chat onWednesday, December 4 at1:45 p.m. ET inCoral Gables, FL. - Piper Sandler’s 35thAnnual Healthcare Conference.Fireside chat on
Thursday, December 5 at9:00 a.m. ET inNew York, NY .
Additional information regarding these events will be available on the Investors section of the argenx website atargenx.com/investors.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the
For further information, please contact:
Media:
Investors:
